POPULARITY
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.
Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.